Knowledge Hub

Global Idiopathic Pulmonary Fibrosis to grow at a CAGR of 23.97% during the period 2016-2020.

Press Release   •   May 16, 2016 09:10 EDT

Description

About Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.

Technavios analysts forecast the Global Idiopathic Pulmonary Fibrosis Market to grow at a CAGR of 23.97% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis.

The market is divided into the following segments based on geography:

Americas

APAC

EMEA

Technavio's report, Global Idiopathic Pulmonary Fibrosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/analysis/717645

Key vendors

Baxter International

Boehringer Ingelheim

F.Hoffmann-La Roche

Prometheus Laboratories

Other prominent vendors

Afferent Pharmaceuticals

Amgen

Biogen

Bristol-Myers Squibb

Cipla

FibroGen

Gilead Sciences

GlaxoSmithKline

GNI Group

Horizon Pharma

ImmuneWorks

MediciNova

MedImmune (subsidiary of AstraZeneca)

Novartis

Pfizer

Promedior

ProMetic Life Sciences

Sanofi

Shionogi

Zai Lab

Market driver

Unmet medical need

For a full, detailed list, view our report

Market challenge

Lack of proper diagnosis

For a full, detailed list, view our report

Market trend

Patient assistance programs

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?